ClinicalTrials.gg
RecruitingNCT04299945Updated May 18, 2026

Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease

An interventional study of concentrated beetroot juice (400mg of nitrate per serving) and concentrated beetroot juice (trace amounts of nitrate per serving) in Interstitial Lung Disease, sponsored by University of British Columbia. Recruiting at 2 sites in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.

Sponsored by University of British Columbia · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Lung Diseases, Interstitial with a site in Canada — 21 open to participants now, 28 under way, 9 of them phase 3. Lung Diseases, Interstitial · Canada.

Planned enrollment
52nd of 57
15 · median 80
Started
2024
with 9 others
No phase
18 of 64
6 open now
Primary completion
2026-12
later than 6 of 27 live
Registered
26th of 64
by date

Among the 64 studies in Lung Diseases, Interstitial with a site in Canada, this one is the 52nd largest by planned enrollment of the 57 interventional ones that give a count, is one of 10 that started in 2024, is one of 18 with no phase, reaches primary completion later than 6 of the 27 other live ones, and was the 26th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

21 of the 64 studies in Lung Diseases, Interstitial with a site in Canada are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Lung Diseases, Interstitial with a site in Canada, or all of them as a file.
02

Study summary

Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD). Optimal methods of exercise training are yet to be explored in ILD. Drinking beetroot juice, which is rich in nitrate, has been shown to improve exercise performance in a variety of groups, but its effects in ILD have not been tested. The purpose of this study is to determine if drinking nitrate-rich beetroot juice can improve exercise performance compared to drinking nitrate-free beetroot juice in people with ILD.

Read the detailed description

PURPOSE:

The primary purpose of this study is to determine the effects of dietary nitrate supplementation on submaximal cycle exercise performance in patients with fibrotic ILD.

HYPOTHESIS:

Our primary hypothesis is that dietary nitrate supplementation will result in greater improvement in submaximal cycle exercise endurance time compared with placebo.

JUSTIFICATION:

Fibrotic interstitial lung disease (ILD) is a heterogeneous group of disorders that cause scarring/fibrosis or inflammation of the lungs, resulting in significant morbidity and high mortality. Almost all ILDs are characterized by dyspnoea and functional limitation and there are few effective and/or well-tolerated pharmacotherapies for many ILD subtypes.

Exertional dyspnoea leads to reduced exercise capacity in ILD, and this functional limitation is further worsened by skeletal muscle weakness and dysfunction. Both dyspnoea and poor exercise tolerance are strongly associated with quality of life and mortality in ILD and thus improving dyspnoea and functional capacity are important goals in the management of ILD.

Pulmonary rehabilitation is a structured evidence-based exercise and education intervention that is recommended for most patients with ILD. Pulmonary rehabilitation improves dyspnoea, functional capacity, and quality of life in patients with ILD; however, these benefits are often modest and only temporary. The exercise component of pulmonary rehabilitation is the predominant mediator of benefit; however, there are no studies that have investigated the optimal method of exercise training in patients with ILD. Thus, there is a clear need to identify new strategies that can provide larger and more persistent benefits from pulmonary rehabilitation.

Nitric oxide (NO) is a physiological signaling molecule that plays a critical role in vascular control. There is accumulating evidence that dietary nitrate, consumed in the form of beetroot juice, can increase the bioavailability of NO and subsequently enhance exercise performance in healthy, elite athlete, as well as diseased populations. These improvements may be related, but not limited to, enhanced efficiency of locomotion, peripheral locomotor oxygen delivery, and/or muscle power. The specific effects of dietary nitrate supplementation in ILD patients has yet to be explored. However, there is great potential for the use of this dietary supplement to improve exercise tolerance during, and improve patient outcomes from, pulmonary rehabilitation.

STATISTICAL ANALYSIS:

A p value \<0.05 will be considered significant for all analyses. Data analysis will be performed using Microsoft Excel 2013 (Microsoft Corporation, Redmond, Washington, US) and Stata v12 (StataCorp, Texas, US).

Primary outcome: The primary outcome of cycle endurance time will be based on the duration patients were able to exercise during the constant work rate exercise test. A t-test will be used to compare endurance times between the intervention and placebo conditions.

The investigators have chosen to power this study based on the primary outcome of change in cycle exercise endurance time. Based on previously collected data in our laboratory in patients with ILD that show a standard deviation of 289.96 seconds for a 75% constant work rate cycle exercise test with a conservative between test correlation of 0.90, the investigators calculated that 15 participants would be needed to detect the minimal clinically important difference of 105 seconds between conditions assuming a two-sided α of 0.05 and 80% power.

03

Conditions studied

  • Interstitial Lung Disease

Keywords

  • ILD
  • Nitrates
  • exercise
  • interstitial lung disease
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses
  • Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis
  • Oxygen saturation ≥92% by pulse oximetry at rest while breathing room air
  • Clinically stable for the preceding 6 weeks
  • Can fluently read and write in English

Exclusion criteria

Exclusion Criteria:

  • to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) (see Table 4 from ERS/ATS consensus statement)
  • Other significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation
  • FVC \<50% or DLCO \<25%
  • Use of prednisone >10 mg/day for >2 weeks within 3 months of the first study visit
  • Cardiac pacemaker or any metal or electronics inside of the body
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Dietary nitrate supplementation

    The dietary nitrate supplement will be a concentrated, nitrate-rich beetroot juice (70 ml providing ∼400mg nitrate per serving)

    Dietary Supplement: concentrated beetroot juice (400mg of nitrate per serving)

  • Placebo comparator
    Placebo

    The placebo will be a concentrated, nitrate-depleted beetroot juice (70 ml with trace amounts of nitrate)

    Dietary Supplement: concentrated beetroot juice (trace amounts of nitrate per serving)

Interventions

  • Dietary supplementconcentrated beetroot juice (400mg of nitrate per serving)

    Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.

  • Dietary supplementconcentrated beetroot juice (trace amounts of nitrate per serving)

    Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.

06

What researchers measure

Primary outcomes

  1. Difference in submaximal cycle exercise endurance time following dietary nitrate supplementation compared to placebo supplementation.

    Exercise endurance time will be measured during submaximal constant load cycle exercise testing.

    Time frame: 1 Week

Secondary outcomes

  1. Difference in exertional dyspnoea during submaximal cycle exercise following dietary nitrate supplementation compared to placebo supplementation.

    Dyspnea rating, measured using the Borg 0-10 category ratio scale, will be assessed at rest and every 1 minute during submaximal constant load cycle exercise testing until exhaustion.

    Time frame: 1 Week

  2. Difference in exertional dyspnoea during activities of daily living following dietary nitrate supplementation compared to placebo supplementation.

    Shortness of breath during daily living patterns will be assessed using established questionnaires.

    Time frame: 1 Week

  3. Difference in concentration of plasma nitrate ([NO3-]) and nitrite ([NO2-]) following dietary nitrate supplementation compared to placebo supplementation.

    Blood samples will be taken and analyzed for the concentration levels of nitrates in blood plasma.

    Time frame: 1 Week

  4. Difference in resting, exercise, and post-exercise blood pressure following dietary nitrate supplementation compared to placebo supplementation.

    Blood pressure will be measured using a manual sphygmomanometer at rest, every 2 minutes during submaximal constant load cycle exercise testing until exhaustion, and 5 minutes after exercise ends.

    Time frame: 1 Week

  5. Difference in oxygen cost of submaximal cycle exercise following dietary nitrate supplementation compared to placebo supplementation.

    Oxygen consumption will be measured during submaximal constant load cycle exercise testing.

    Time frame: 1 Week

  6. Difference in peripheral locomotor muscle oxygenation following dietary nitrate supplementation compared to placebo supplementation.

    Peripheral locomotor muscle oxygenation will be monitored using near-infrared spectroscopy during submaximal constant load exercise testing.

    Time frame: 1 Week

  7. Difference in post-exercise quadriceps fatigue following dietary nitrate supplementation compared to placebo supplementation.

    Quadriceps fatigue will be assessed by measuring the quadriceps muscle force output using the femoral magnetic stimulation technique immediately before and after submaximal constant load exercise testing.

    Time frame: 1 Week

07

Study locations

2 of 2 sites recruiting
  • Providence Health Care - St. Paul's Hosptial
    Vancouver, British Columbia V6Z 1Y6, Canada
    Recruiting
  • Vancouver Coastal Health
    Vancouver, V5Z 1M9, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.

Of 114 non-industry interventional studies with no phase under Lung Diseases, Interstitial, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 28 months is close to that.

Counting every sponsor, half of 119 studies reached it within 27 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2020
First posted
Mar 9, 2020
StartActual
Aug 7, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04299945
Responsible party
Jordan Guenette (Director of Cardiopulmonary Exercise Physiology Laboratory, University of British Columbia) — Principal investigator
First posted
Mar 9, 2020
Start date
Aug 7, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 18, 2026

Study contacts

Olivia Ferguson, MSc
Contact
Olivia.Ferguson@hli.ubc.ca
604-806-8835
Dhillon Satvir, MSc
Contact
satvir.dhillon@hli.ubc.ca
604-806-8835

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion